Scopus
YÖKSİS DOI Eşleşti
SJR Q1
Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
Investigational New Drugs · Haziran 2022
YÖKSİS Kayıtları
Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
Investigational New Drugs · 2022 SCI-Expanded
Prof. Dr. ESMA MENEVŞE →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
2022 ISSN: 0167-6997 SCI-Expanded Q2
Prof. Dr. ESMA MENEVŞE →
Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway
2023 ISSN: 0167-6997 SCI-Expanded Q2
Prof. Dr. MUSTAFA ÖZMEN →
Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway
2023 ISSN: 0167-6997 SCI-Expanded Q2
Prof. Dr. AHMED NURİ KURŞUNLU →
Makale Bilgileri
ISSN01676997
Yayın TarihiHaziran 2022
Cilt / Sayfa40 · 519-528
Scopus ID2-s2.0-85124228958
Özet
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors of the pancreas. Preclinical studies show that it evades the immune system with immune checkpoints and promotes tumor development. V-domain Ig suppressor of T cell activation (VISTA) is a new immune-check point from the B7 family and is highly expressed in cancer cells. Overexpression of toll like receptor 4 (TLR4) in pancreatic adenocarcinoma is associated with induced tumorigenesis, tumor growth, resistancy to chemotherapy. Naloxone is an opioid and inhibits TLR4-ligand association. In this study, we investigated the relation of TLR4 and downstream pathways with immune-check point VISTA in pancreatic cancer proliferation. We initially collected pancreatic cancer-related datasets using the GEPIA2 and UALCAN databases. Based on this data obtained the effect of various concentrations and incubation times of naloxone were used on PANC-1 cells proliferation. A combination of naloxone and VISTA-siRNA were applied, and the effect of both naloxone and combined treatment on TLR4, Interleukin 1 receptor associated kinase 4 (IRAK4) and VISTA gene expression were analyzed in pancreatic cancer cells. As a result of analysis with Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR), gene expression levels of TLR4, IRAK4 and VISTA were significantly suppressed and cell proliferation was significantly reduced. We found that administration of naloxone and VISTA-siRNA in combination with PDAC cells suppressed signaling. Therefore, we considered that the relationship between VISTA and TLR4 signaling pathways and the other possible associated signal molecules may be an important marker in determining the response of immune checkpoint inhibitors in cancer treatment.
Yazarlar (5)
1
Kubra Sena Bas Topcu
ORCID: 0000-0003-3161-1042
2
Emine N. Korucu
3
Esma Menevşe
4
Nadir Koçak
ORCID: 0000-0002-1104-1292
5
Tugce Duran
ORCID: 0000-0002-7353-4527
Anahtar Kelimeler
Immunotherapy
Pancreatic ductal adenocarcinoma
siRNA
TLR4
VISTA
Kurumlar
Bartin Üniversitesi
Bartin Turkey
Karatay Üniversitesi
Konya Turkey
Necmettin Erbakan Üniversitesi
Meram Turkey
Selçuk Tip Fakültesi
Konya Turkey
Scimago Dergi (ISSN Eşleşmesi)
Investigational New Drugs
Q1
SJR Skoru1,074
H-Index100
YayıncıSpringer
ÜlkeUnited States
Pharmacology (Q1)
Pharmacology (medical) (Q1)
Oncology (Q2)
Metrikler
14
Atıf
5
Yazar
5
Anahtar Kelime